Loading...
•
Sep 30, 2023
Regeneron Q3 2023 Earnings Report
Regeneron's financial performance was driven by growth in Dupixent and Libtayo sales, as well as initial uptake of EYLEA HD, resulting in a 15% increase in total revenue compared to Q3 2022.
Key Takeaways
Regeneron reported a strong third quarter in 2023, with a 15% increase in revenue to $3.36 billion. This growth was primarily driven by Dupixent and Libtayo, along with the launch of EYLEA HD. The company also highlighted pipeline advancements, including FDA priority review designations for odronextamab and Dupixent.
Total revenues increased by 15% to $3.36 billion compared to Q3 2022.
Dupixent global net sales (recorded by Sanofi) increased by 33% to $3.10 billion compared to Q3 2022.
U.S. net sales for EYLEA and EYLEA HD were $1.49 billion, including $43 million from EYLEA HD.
Libtayo global net sales increased by 62% to $232 million compared to Q3 2022.
Revenue by Segment
Forward Guidance
Regeneron provided full year 2023 financial guidance, including GAAP and non-GAAP R&D, SG&A, gross margin on net product sales, COCM, capital expenditures, and effective tax rate.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...